Browsing Tag
Jeremy Abramson
1 post
Genentech’s Columvi combo fails to secure FDA approval for second-line DLBCL use
FDA rejects Genentech’s sBLA for Columvi-GemOx in second-line DLBCL treatment; survival benefit data deemed insufficient for U.S. approval.